Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant

Stephen Michael Clark, Amber B. Clemmons, Lindsay Schaack, Jeonifer Garren, David L. Deremer, Vamsi K. Kota

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Purpose To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Methods In a single-center cohort study patients receiving melphalan containing hematopoietic stem cell transplantation regimens who received a one-time dose of 150 mg IV fosaprepitant (n = 56) were compared to a historical control (n = 70). Results The primary endpoint of no emesis from melphalan administration through five days afterward was 80% for the fosaprepitant group versus 66% in the control group (p = 0.068). Addition of fosaprepitant demonstrated significant improvement in emetic episodes per patient during the entire assessment period (p = 0.011) and days 1-5 after melphalan (p = 0.045). Fosaprepitant resulted in no substantial nausea during the entire assessment period in 37% of high-dose melphalan patients and 57% of BEAM patients. Conclusions Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting.

Original languageEnglish (US)
Pages (from-to)416-422
Number of pages7
JournalJournal of Oncology Pharmacy Practice
Volume22
Issue number3
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Keywords

  • fosaprepitant
  • hematopoietic stem cell transplant
  • nausea
  • vomiting

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant'. Together they form a unique fingerprint.

  • Cite this